99 related articles for article (PubMed ID: 20829830)
21. Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization.
Moseri A; Sinha E; Zommer H; Arshava B; Naider F; Anglister J
Vaccine; 2017 Jan; 35(2):222-230. PubMed ID: 27939012
[TBL] [Abstract][Full Text] [Related]
22. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
[TBL] [Abstract][Full Text] [Related]
23. AIDS/HIV. Host controls of HIV neutralizing antibodies.
Haynes BF; Verkoczy L
Science; 2014 May; 344(6184):588-9. PubMed ID: 24812389
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
[TBL] [Abstract][Full Text] [Related]
25. Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120.
Yu JS; Liao HX; Pritchett J; Bowman C; Vivian C; Parks R; Xia SM; Cooper M; Williams WB; Bonsignori M; Reed SG; Chen M; Vandergrift N; Rice CM; Haynes BF
J Virol Methods; 2017 Nov; 249():85-93. PubMed ID: 28837840
[TBL] [Abstract][Full Text] [Related]
26. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker LG; Hoelscher M; Maboko L; Makhema J; Robb ML; Abdool Karim S; Abdool Karim Q; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
PLoS Pathog; 2016 Jul; 12(7):e1005742. PubMed ID: 27434311
[TBL] [Abstract][Full Text] [Related]
27. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
Wrin T; Nunberg JH
AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
[No Abstract] [Full Text] [Related]
28. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
[TBL] [Abstract][Full Text] [Related]
29. An HIV-1 vaccine based on bacterium-like particles elicits Env-specific mucosal immune responses.
Bi J; Li F; Zhang M; Wang H; Lu J; Zhang Y; Ling H; Wang J; Gao F; Kong W; Yu B; Yu X
Immunol Lett; 2020 Jun; 222():29-39. PubMed ID: 32173375
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
31. GP120: target for neutralizing HIV-1 antibodies.
Pantophlet R; Burton DR
Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
[TBL] [Abstract][Full Text] [Related]
32. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12.
Duenas-Decamp MJ; Clapham PR
J Virol; 2010 Sep; 84(18):9608-12. PubMed ID: 20610714
[TBL] [Abstract][Full Text] [Related]
34. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.
Gilbert P; Wang M; Wrin T; Petropoulos C; Gurwith M; Sinangil F; D'Souza P; Rodriguez-Chavez IR; DeCamp A; Giganti M; Berman PW; Self SG; Montefiori DC
J Infect Dis; 2010 Aug; 202(4):595-605. PubMed ID: 20608874
[TBL] [Abstract][Full Text] [Related]
35. Antibody neutralization of human immunodeficiency virus type 1 (HIV-1).
Schønning K
APMIS Suppl; 2003; (111):1-42. PubMed ID: 12739253
[No Abstract] [Full Text] [Related]
36. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
Montefiori DC; Evans TG
AIDS Res Hum Retroviruses; 1999 May; 15(8):689-98. PubMed ID: 10357464
[No Abstract] [Full Text] [Related]
37. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
[TBL] [Abstract][Full Text] [Related]
38. AIDS research. Novel antibody response may explain HIV vaccine success.
Cohen J
Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
[No Abstract] [Full Text] [Related]
39. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
40. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
